Genomics Institute of the Novartis Research Foundation
Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.
IRM LLC
A A A A A A A A A A A A A A A A A A A A A A A A A A C A A A A A A A A A A A A A A A A A
A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Juliet Valentina Xiaolin Vince Xiaodong Jon Donatella
Nabakka Molteni Li Yeh Liu Loren Chianelli